A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects

This study is an open-label, non-randomized, metabolism and excretion study of a single 2 mg
IV dose of [14C] TRV130 (approximately 100 µCi) administered as a 10 mL manual IV push over
2 minutes in a fasted state.

Key Inclusion Criteria:

- Males, between 18 and 64 years of age, inclusive

- With body weight ≥ 50 kg and body mass index (BMI) between 18 and 32 kg/m2, inclusive

- In good health, determined by no clinically significant findings from medical
history, 12-lead ECG, and vital signs

- Negative test for selected drugs of abuse at Screening and at Check-in

- Able to comprehend and willing to sign an Informed Consent Form (ICF) prior to any
study procedure

- A typical minimum of 1 to 2 bowel movements per day

Key Exclusion Criteria:

- History of sensitivity to any of the study medications or components thereof or a
history of medication or other allergy that, in the opinion of the Investigator,
contraindicates their participation

- Participation in any other investigational study drug trial in which receipt of an
investigational study drug occurred within 28 days prior to Check-in

- Participation in any other radiolabeled investigational study drug trial within 12
months prior to Check-in

- Exposure to significant radiation (eg, serial x-ray or computed tomography scans,
barium meal, current employment in a job requiring radiation exposure monitoring)
within 12 months prior to Check-in

- Has current malignancy, current systemic chemotherapy, or cancer diagnosis within 5
years prior to Screening (excluding squamous or basal cell carcinoma of the skin that
has been clinically stable and fully excised in a curative procedure);

- Use of any tobacco- or nicotine-containing products within 6 months prior to
Screening